DOCSLIB.ORG

Supplemental Information Exercise and Metformin Counteract Altered Mitochondrial Function in the Insulin Resistant Brain Gregory

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Information Exercise and Metformin Counteract Altered Mitochondrial Function in the Insulin Resistant Brain Gregory Supplemental Information Exercise and metformin counteract altered mitochondrial function in the insulin resistant brain 1 1 2 1 Gregory N. Ruegsegger , Patrick M. Vanderboom , Surendra Dasari , Katherine A. Klaus , Parijat Kabiraj3, Christina B McCarthy3. Claudia F. Lucchinetti3, 4, K. Sreekumaran Nair1* Affiliations 1 Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA 2 Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA 3 Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA 4 Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA. Figure S1. Aerobic exercise attenuates weight gain, inflammation, and increased ceramide content accompanying HFD. (A-B) 4 weeks of HFD led to greater body weight (A) and body fat (B), which was corrected in HFD-EX (n = 16-17) [for panel A: *p < 0.05: HFD-SED vs. Chow-SED; # p < 0.05: HFD-EX vs. HFD-SED; ‡ p < 0.05: Chow-EX vs. Chow-SED]. (C) Food intake was greater in HFD-fed mice independent of exercise status, while exercise increased food intake in Chow-fed mice (n = 10). (D) HFD did not influence running distance (n = 17). (E) Tnfa, Il1b, and Il6 mRNA expression was higher in the hypothalamus (hypo), hippocampus (hippo), and cortex of HFD-SED mice, which was partially attenuated in HFD-EX (n = 6). (F) C16:0, C18:0, C20:0, and C22:0 ceramides were greater in the hippocampus of HFD-SED, which was corrected in HFD-EX (n = 6). (G) Cer1, Cer2, Cer4 mRNA expression in the hippocampus did not differ between groups (n = 6) Data represent means ± SEM and were analyzed with two-way ANOVA followed by Tukey’s multiple comparisons post hoc test (A-G); *p < 0.05, **p < 0.01, ***p <0.001. Figure S2. Aerobic exercise corrects altered mitochondrial respiration accompanying HFD. (A) State 3 mitochondrial respiration in isolated cerebral mitochondria was lower in HFD- SED, which was corrected in HFD-EX (n = 10-11). (B) The respiratory control ratio (RCR), which is indicative of mitochondrial coupling, was lower in HFD-SED, and normalized in HFD- EX (n = 10-11). Data represent means ± SEM and were analyzed with two-way ANOVA followed by Tukey’s multiple comparisons post hoc test; *p < 0.05. Figure S3. Intranasal insulin receptor antagonism influences mitochondrial respiration. (A-B) Daily intranasal injection of the insulin receptor antagonist S961 for 7 days did not influence plasma glucose (A) and insulin (B) concentrations (n = 8). (C) S961 increased state 4 mitochondrial respiration in isolated cerebral mitochondria (n = 8). (D) S961 decreased the respiratory control ratio (RCR), indicative of uncoupled mitochondrial respiration (n = 8). Data represent means ± SEM and were analyzed with two-tailed Student’s t-test; **p < 0.01. Figure S4. Intranasal S961 blocKs exercised-induced in glucose and insulin tolerance. (A- B) Exercise attenuated gains in body weight (A) and body fat (B) independent of S961 treatment (n = 8). (C) HFD and exercise independently increased food intake independent of S961 treatment (n = 8). (D) S961 did not alter voluntary running distance (n = 8). (E-F) S961 prevented exercise-induced improvements in fasting plasma glucose (E) and insulin (F) in HFD- fed mice (n = 7). (G-H) S961 prevented exercise-induced improvements in oral glucose tolerance (G) and intraperitoneal insulin tolerance (H) in HFD-fed mice (n = 7). Data represent means ± SEM and were analyzed with Mixed Model Analysis and Student’s t-test post hoc comparisons; *p < 0.05: HFD-SED vs. Chow-SED; # p < 0.05: HFD-EX vs. HFD-SED; † p < 0.05: HFD-EX vs. HFD-EX + S961; ‡ p < 0.05: HFD-EX vs. Chow-SED. Figure S5. Metformin crosses the blood-brain barrier. (A-B) Metformin administration in drinking water dose-dependently increased metformin concertation in plasma (A) and hippocampal tissue (B) (n = 3). (C) Metformin administration in drinking water dose-dependently increased AMPK phosphorylation at Thr-172 in the hippocampus (n = 3). Data represent means ± SEM and were analyzed with two-tailed Student’s t-test; *p < 0.05. Figure S6. Metformin improves whole-body glucose and insulin tolerance. (A) Following 4-weeks of HFD, mice were provided ad libitum (HFD-AL), HFD provided ad libitum while receiving metformin (2mg/mL; ~300mg/kg/day) in the drinking water (HFD-MFN), or HFD restricted to 85% (HFD-PF) for 8 additional weeks. HFD-PF and HFD-MFN prevented further gains in body weight compared to HFD-AL (n = 9-10). (B) HFD-MFN and HFD-PF attenuated gains in body fat compared to HFD-AL (n = 9-10). (C) HFD-AL lead to greater food intake, which was partially attenuated in HFD-MFN (n = 9-10). (D-E) HFD-AL increased fasting plasma glucose (D) and insulin (E) which were partially attenuated in HFD-AL and further reduced in HFD-MFN (n = 9-10). (F-G) HFD-AL increased oral glucose tolerance (F) and intraperitoneal insulin tolerance (G) which were partially attenuated in HFD-AL and further reduced in HFD- MFN (n = 9-10) (H) AMPK phosphorylation at Thr-172 in the hippocampus was increased by HFD independent of treatment (n = 6). Data represent means ± SEM and were analyzed with Mixed Model Analysis and Student’s t-test post hoc comparisons. Symbols in panels A-E, H: *p < 0.05 compared to Chow; # p < 0.05 compared to HFD-MFN; † p < 0.05 compared to HFD-AL. Symbols in panels F, G: *p < 0.05: Chow vs. HFD-AL; # p < 0.05: HFD-AL vs. HFD-MFN; † p < 0.05: HFD-AL vs. HFD-PF; ‡ p < 0.05: HFD-PF vs. HFD-MFN; ¶ p < 0.05: Chow vs. HFD-MFN. Figure S7. Metformin corrects altered mitochondrial respiration accompanying HFD. (A) State 3 mitochondrial respiration in isolated cerebral mitochondria was lower in HFD-SED, which was corrected in HFD-MFN (n = 9-10). (B) The respiratory control ratio (RCR) was lower in HFD-SED and HFD-PF, and normalized in HFD-MFN (n = 9-10). Data represent means ± SEM and were analyzed with Mixed Model Analysis and Student’s t-test post hoc comparisons; *p < 0.05, ** p < 0.01. Table S1. Individual protein differential expression data from the 159 significantly affected proteins shown in the Figure 3A volcano plot (Chow-SED vs. HFD-SED comparison). Table lists protein symbols, and names as given by UniProt database, together with their expression ratio (in log2 scale), FDR (in log2 scale) and protein affiliate group as shown in Figure 3A (Group). Protein group was determined by cross-reference against the MitoCarta database from protein affiliation. Proteins are listed by log2 fold-change from most up-regulated to most-downregulated in HFD-SED compared to Chow-SED. Gene Symbol Log2 (HFD-SED/Chow-SED) Log2FDR Group H2-M10.3 29.81 7.32 Ptpn12 28.68 7.38 Ccdc175 27.29 7.07 Mrpl2 27.08 7.32 Mitochondrial Cwf19l2 26.92 4.60 Thg1l 25.97 8.76 Mitochondrial Mrpl53 25.89 8.14 Mitochondrial Rundc3b 25.89 7.38 Ccdc170 25.56 7.38 Tifa 25.13 18.12 Tor2a 24.48 5.71 S100a1 24.39 7.37 Ranbp17 23.44 5.77 Cacna1h 21.85 7.28 Ppig 20.82 4.94 Unc5a 3.49 5.82 Apoa4 3.15 8.55 Ndufs6 2.97 4.76 Mitochondrial Dnal1 2.73 5.86 Vimp 2.61 5.70 Lrrc20 2.21 19.55 Ccdc115 2.13 5.87 Fhl2 2.06 11.59 Commd8 2.02 7.38 Prrt1 1.97 11.39 Fkbp1a 1.88 4.60 H1fx 1.71 12.56 Ercc1 1.69 26.76 Nrp2 1.66 7.20 Pcsk2 1.62 7.47 Ociad1 1.58 6.11 Mitochondrial Macrod2 1.58 7.47 Fmnl2 1.46 9.94 Ddn 1.45 5.10 Tceal6 1.44 6.68 Lpin2 1.44 7.26 Pdzd2 1.41 5.55 Rwdd4 1.40 10.88 Txn 1.38 7.87 Mitochondrial Pycard 1.38 8.35 Jph3 1.37 5.96 Rpl18a 1.30 9.29 Dbi 1.30 6.33 Nek9 1.28 5.42 Mif 1.26 10.40 Ppp1cb 1.25 4.65 Kiaa1671 1.23 6.24 Cox5a 1.22 16.76 Mitochondrial Tceal5 1.20 6.46 Tmem263 1.19 4.39 Fibp 1.16 4.52 Pnck 1.12 4.94 Crym 1.05 4.60 Naip6 1.05 5.18 Hpca 1.04 5.49 Gm10020 1.02 10.15 Nebl 1.02 17.19 Synpr 1.02 7.79 Trappc1 0.98 4.60 Ptprs 0.96 18.21 Arpc2 0.91 18.12 Mtmr12 0.91 5.10 Ccdc43 0.90 7.55 Kbtbd11 0.89 5.42 Asphd2 0.88 9.75 Dgkb 0.88 6.33 Ube2g2 0.87 7.38 Capzb 0.87 4.68 Hebp1 0.86 7.26 Ncs1 0.82 6.33 Ccsap 0.80 5.07 Eif3d 0.80 6.56 Frrs1l 0.80 6.74 Kctd12 0.78 7.29 Fdx1l 0.77 4.52 Mitochondrial Begain 0.75 6.20 Cpeb4 0.74 5.12 Letmd1 0.74 7.38 Mitochondrial Rogdi 0.73 7.22 Anks1b 0.72 11.39 Coq3 0.71 6.93 Mitochondrial Srr 0.71 5.09 Nfu1 0.71 5.77 Mitochondrial Mcu 0.71 33.49 Mitochondrial Faah 0.69 6.94 Stxbp6 0.68 9.29 Dcakd 0.66 4.52 Mitochondrial Grb2 0.65 12.30 Csnk2b 0.63 5.16 Adprh 0.62 6.96 Cttnbp2 0.60 12.80 Cenpv 0.60 7.37 Chchd6 0.59 5.96 Mitochondrial Nptxr 0.59 5.30 Mta1 0.58 5.42 Map6d1 0.57 6.68 Pebp1 0.55 10.01 Mgll 0.54 7.26 Sdcbp 0.53 6.25 Ak4 0.53 7.59 Mitochondrial Src 0.52 8.09 Acy1 -0.51 19.63 Gap43 -0.51 6.95 Mettl7a1 -0.52 6.24 Atg2b -0.56 7.29 Vat1 -0.60 5.73 Acaa2 -0.61 4.42 Mitochondrial Osbpl1a -0.64 5.78 Suclg2 -0.65 4.65 Mitochondrial Trim23 -0.65 5.98 Aplp2 -0.67 7.78 Enpp6 -0.67 5.86 Mag -0.69 8.74 Syt2 -0.70 4.52 Tpp1 -0.76 6.09 9030624J02Rik -0.78 4.76 Btbd17 -0.79 12.30 Eml1 -0.80 9.29 Atpaf1 -0.89 4.46 Mitochondrial Arf2 -0.93 6.71 Pygm -0.97 7.80 Xdh -1.04 6.89 Sccpdh -1.05 12.30 Mitochondrial Fntb -1.06 4.73 Astn2 -1.08 7.38 Esyt1 -1.12 15.34 Ptgfrn -1.19 9.46 Trdn -1.21 20.27 Limk1 -1.24 7.60 Ctnna3 -1.36 5.46 Serpinh1 -1.40 7.75 Itih5 -1.47 4.69 Cbln1 -1.72 5.47 Elovl5 -1.75 8.57 Hbs1l -1.78 8.26 C3 -1.85 12.30 Kcnj10 -1.97 4.82 Rplp2 -2.32 5.27 Krt79 -2.69 5.71 Krt13 -2.74 5.86 Zmat4 -2.76 7.85 Pcdha9 -2.88 11.56 Fxyd1 -3.28 6.10 Faxc -3.29 5.96 Lsm3 -3.88 5.42 Rbx1 -3.98 8.44 mt-Nd3 -23.72 7.38 P2rx5 -24.08 7.38 Gm5814 -24.67 7.38 Nexn -25.05 7.38 Uaca -25.15 6.47 Ccdc12 -25.16 7.09 Fbxo45 -25.53 7.29 Spag1 -25.77 7.38 Trpv3 -27.74 6.93 Wdr93 -28.12 7.38 Timm10b -28.68 10.06 Ddx18 -29.67 7.20 Efcab5 -30.77 7.06 Table S2.
Load more

Recommended publications
  • Supplementary Materials
    DEPs in osteosarcoma cells comparing to osteoblastic cells Biological Process Protein Percentage of Hits metabolic process (GO:0008152) 29.3 29.3% cellular process (GO:0009987) 20.2 20.2% localization (GO:0051179) 9.4 9.4% biological regulation (GO:0065007) 8 8.0% developmental process (GO:0032502) 7.8 7.8% response to stimulus (GO:0050896) 5.6 5.6% cellular component organization (GO:0071840) 5.6 5.6% multicellular organismal process (GO:0032501) 4.4 4.4% immune system process (GO:0002376) 4.2 4.2% biological adhesion (GO:0022610) 2.7 2.7% apoptotic process (GO:0006915) 1.6 1.6% reproduction (GO:0000003) 0.8 0.8% locomotion (GO:0040011) 0.4 0.4% cell killing (GO:0001906) 0.1 0.1% 100.1% Genes 2179Hits 3870 biological adhesion apoptotic process … reproduction (GO:0000003) , 0.8% (GO:0022610) , 2.7% locomotion (GO:0040011) ,… immune system process cell killing (GO:0001906) , 0.1% (GO:0002376) , 4.2% multicellular organismal process (GO:0032501) , metabolic process 4.4% (GO:0008152) , 29.3% cellular component organization (GO:0071840) , 5.6% response to stimulus (GO:0050896), 5.6% developmental process (GO:0032502) , 7.8% biological regulation (GO:0065007) , 8.0% cellular process (GO:0009987) , 20.2% localization (GO:0051179) , 9.
    [Show full text]
  • Supplementary Materials: Evaluation of Cytotoxicity and Α-Glucosidase Inhibitory Activity of Amide and Polyamino-Derivatives of Lupane Triterpenoids
    Supplementary Materials: Evaluation of cytotoxicity and α-glucosidase inhibitory activity of amide and polyamino-derivatives of lupane triterpenoids Oxana B. Kazakova1*, Gul'nara V. Giniyatullina1, Akhat G. Mustafin1, Denis A. Babkov2, Elena V. Sokolova2, Alexander A. Spasov2* 1Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences, 71, pr. Oktyabrya, 450054 Ufa, Russian Federation 2Scientific Center for Innovative Drugs, Volgograd State Medical University, Novorossiyskaya st. 39, Volgograd 400087, Russian Federation Correspondence Prof. Dr. Oxana B. Kazakova Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences 71 Prospeсt Oktyabrya Ufa, 450054 Russian Federation E-mail: [email protected] Prof. Dr. Alexander A. Spasov Scientific Center for Innovative Drugs of the Volgograd State Medical University 39 Novorossiyskaya st. Volgograd, 400087 Russian Federation E-mail: [email protected] Figure S1. 1H and 13C of compound 2. H NH N H O H O H 2 2 Figure S2. 1H and 13C of compound 4. NH2 O H O H CH3 O O H H3C O H 4 3 Figure S3. Anticancer screening data of compound 2 at single dose assay 4 Figure S4. Anticancer screening data of compound 7 at single dose assay 5 Figure S5. Anticancer screening data of compound 8 at single dose assay 6 Figure S6. Anticancer screening data of compound 9 at single dose assay 7 Figure S7. Anticancer screening data of compound 12 at single dose assay 8 Figure S8. Anticancer screening data of compound 13 at single dose assay 9 Figure S9. Anticancer screening data of compound 14 at single dose assay 10 Figure S10.
    [Show full text]
  • DHX38 Antibody - Middle Region Rabbit Polyclonal Antibody Catalog # AI10980
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 DHX38 antibody - middle region Rabbit Polyclonal Antibody Catalog # AI10980 Specification DHX38 antibody - middle region - Product Information Application WB Primary Accession Q92620 Other Accession NM_014003, NP_054722 Reactivity Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Horse, Bovine, Dog Predicted Human, Rat, WB Suggested Anti-DHX38 Antibody Rabbit, Zebrafish, Titration: 1.0 μg/ml Pig, Chicken Positive Control: OVCAR-3 Whole Cell Host Rabbit Clonality Polyclonal Calculated MW 140kDa KDa DHX38 antibody - middle region - Additional Information Gene ID 9785 Alias Symbol DDX38, KIAA0224, PRP16, PRPF16 Other Names Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16, 3.6.4.13, ATP-dependent RNA helicase DHX38, DEAH box protein 38, DHX38, DDX38, KIAA0224, PRP16 Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. Reconstitution & Storage Add 50 ul of distilled water. Final anti-DHX38 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. Precautions Page 1/2 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 DHX38 antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures. DHX38 antibody - middle region - Protein Information Name DHX38 Synonyms DDX38, KIAA0224, PRP16 Function Probable ATP-binding RNA helicase (Probable). Involved in pre-mRNA splicing as component of the spliceosome (PubMed:<a href="http://www.uniprot.org/c itations/29301961" target="_blank">29301961</a>, PubMed:<a href="http://www.uniprot.org/ci tations/9524131" target="_blank">9524131</a>).
    [Show full text]
  • Mapping Autosomal Recessive Intellectual Disability: Combined Microarray and Exome
    bioRxiv preprint doi: https://doi.org/10.1101/092346; this version posted March 15, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Mapping Autosomal Recessive Intellectual Disability: Combined Microarray and Exome Sequencing Identifies 26 Novel Candidate Genes in 192 Consanguineous Families Ricardo Harripaul, MSc1,2, Nasim Vasli, PhD1, Anna Mikhailov, BSc1, Muhammad Arshad Rafiq, PhD 1,3, Kirti Mittal, PhD 1, Christian Windpassinger, PhD4, Taimoor I. Sheikh, MPhil1,2, Abdul Noor, PhD5,6, Huda Mahmood, BSc1, Samantha Downey1,7, Maneesha Johnson1,7, Kayla Vleuten1,7, Lauren Bell1,7, Muhammad Ilyas, M.Phil8, Falak Sher Khan, MS9, Valeed Khan, MS9, Mohammad Moradi, MSc10, Muhammad Ayaz11, Farooq Naeem, PhD 11,12, Abolfazl Heidari, PhD1,13, Iltaf Ahmed, PhD14, Shirin Ghadami, PhD15, Zehra Agha, PhD3, Sirous Zeinali, PhD15, Raheel Qamar, PhD3,16, Hossein Mozhdehipanah, MD17, Peter John, PhD14, Asif Mir, PhD8, Muhammad Ansar, PhD9, Leon French, PhD18, Muhammad Ayub, MBBS, MD11,12, John B. Vincent, PhD1,2,19 1Molecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; 2Institute of Medical Science, University of Toronto, Toronto, ON, Canada; 3Dept. of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan; 4Institute of Human Genetics, Medical University of Graz, Graz, Austria; 5Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; 6 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; 1 bioRxiv preprint doi: https://doi.org/10.1101/092346; this version posted March 15, 2017.
    [Show full text]
  • Genome-Wide Analysis of DNA Methylation In
    Villalba‑Benito et al. Clin Epigenet (2021) 13:51 https://doi.org/10.1186/s13148‑021‑01040‑6 RESEARCH Open Access Genome‑wide analysis of DNA methylation in Hirschsprung enteric precursor cells: unraveling the epigenetic landscape of enteric nervous system development Leticia Villalba‑Benito1,2, Daniel López‑López3,4, Ana Torroglosa1,2, Carlos S. Casimiro‑Soriguer3,4, Berta Luzón‑Toro1,2, Raquel María Fernández1,2, María José Moya‑Jiménez5, Guillermo Antiñolo1,2, Joaquín Dopazo2,3,4 and Salud Borrego1,2* Abstract Background: Hirschsprung disease (HSCR, OMIM 142623) is a rare congenital disorder that results from a failure to fully colonize the gut by enteric precursor cells (EPCs) derived from the neural crest. Such incomplete gut coloniza‑ tion is due to alterations in EPCs proliferation, survival, migration and/or diferentiation during enteric nervous system (ENS) development. This complex process is regulated by a network of signaling pathways that is orchestrated by genetic and epigenetic factors, and therefore alterations at these levels can lead to the onset of neurocristopathies such as HSCR. The goal of this study is to broaden our knowledge of the role of epigenetic mechanisms in the disease context, specifcally in DNA methylation. Therefore, with this aim, a Whole‑Genome Bisulfte Sequencing assay has been performed using EPCs from HSCR patients and human controls. Results: This is the frst study to present a whole genome DNA methylation profle in HSCR and reveal a decrease of global DNA methylation in CpG context in HSCR patients compared with controls, which correlates with a greater hypomethylation of the diferentially methylated regions (DMRs) identifed.
    [Show full text]
  • A Network Propagation Approach to Prioritize Long Tail Genes in Cancer
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.05.429983; this version posted February 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. A Network Propagation Approach to Prioritize Long Tail Genes in Cancer Hussein Mohsen1,*, Vignesh Gunasekharan2, Tao Qing2, Sahand Negahban3, Zoltan Szallasi4, Lajos Pusztai2,*, Mark B. Gerstein1,5,6,3,* 1 Computational Biology & Bioinformatics Program, Yale University, New Haven, CT 06511, USA 2 Breast Medical Oncology, Yale School of Medicine, New Haven, CT 06511, USA 3 Department of Statistics & Data Science, Yale University, New Haven, CT 06511, USA 4 Children’s Hospital Informatics Program, Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 02115, USA 5 Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511, USA 6 Department of Computer Science, Yale University, New Haven, CT 06511, USA * Corresponding author Abstract Introduction. The diversity of genomic alterations in cancer pose challenges to fully understanding the etiologies of the disease. Recent interest in infrequent mutations, in genes that reside in the “long tail” of the mutational distribution, uncovered new genes with significant implication in cancer development. The study of these genes often requires integrative approaches with multiple types of biological data. Network propagation methods have demonstrated high efficacy in uncovering genomic patterns underlying cancer using biological interaction networks. Yet, the majority of these analyses have focused their assessment on detecting known cancer genes or identifying altered subnetworks.
    [Show full text]
  • Sequences in the Cytoplasmic Tail of SARS-Cov-2 Spike Facilitate Expression at the Cell Surface and Syncytia Formation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.12.335562; this version posted May 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation Jerome Cattin-Ortolá1,2, Lawrence Welch1,2, Sarah L. Maslen1, J. Mark Skehel1, Guido Papa1, Leo C. James1 and Sean Munro1* 1: MRC Laboratory oF Molecular Biology Francis Crick Avenue Cambridge CB2 0QH UK 2: Denotes equal contribution * Corresponding author: Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.10.12.335562; this version posted May 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract The Spike (S) protein of SARS-CoV-2 binds ACE2 to direct fusion with host cells. S comprises a large external domain, a transmembrane domain (TMD) and a short cytoplasmic tail. Understanding the intracellular trafficking of S is relevant to SARS-CoV-2 infection, and to vaccines expressing full-length S from mRNA or adenovirus vectors. We have applied proteomics to identify cellular factors that interact with the cytoplasmic tail of S.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Elucidation of the Function of Type 1 Human Methionine Aminopeptidase During Cell Cycle Progression
    Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression Xiaoyi Hu*, Anthony Addlagatta†, Jun Lu*, Brian W. Matthews†‡, and Jun O. Liu*‡§ *Department of Pharmacology and Molecular Sciences and §Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205; and †Institute of Molecular Biology, Howard Hughes Medical Institute and Department of Physics, University of Oregon, Eugene, OR 97403-1229 Contributed by Brian W. Matthews, October 4, 2006 (sent for review September 7, 2006) Processing of the N-terminal initiator methionine is an essential notion that HsMetAP2 plays an important role in endothelial cell cellular process conserved from prokaryotes to eukaryotes. The proliferation and is likely to mediate inhibition of endothelial cells enzymes that remove N-terminal methionine are known as methi- by fumagillin and related analogs (5, 6, 9). onine aminopeptidases (MetAPs). Human MetAP2 has been shown In contrast to HsMetAP2, little is known about the physiological to be required for the proliferation of endothelial cells and angio- function of human MetAP1, although genetic studies in yeast have genesis. The physiological function of MetAP1, however, has suggested a more dominant role for ScMetAP1, as evidenced by the remained elusive. In this report we demonstrate that a family of more severe growth defect observed in ScMetAP1 knockout strain inhibitors with a core structure of pyridine-2-carboxylic acid pre- than that in ScMetAP2 knockout strain (10). There has also been viously developed for the bacterial and yeast MetAP1 is also circumstantial evidence implicating a role of HsMetAP1 in tumor specific for human MetAP1 (HsMetAP1), as confirmed by both cell proliferation.
    [Show full text]
  • Functional Parsing of Driver Mutations in the Colorectal Cancer Genome Reveals Numerous Suppressors of Anchorage-Independent
    Supplementary information Functional parsing of driver mutations in the colorectal cancer genome reveals numerous suppressors of anchorage-independent growth Ugur Eskiocak1, Sang Bum Kim1, Peter Ly1, Andres I. Roig1, Sebastian Biglione1, Kakajan Komurov2, Crystal Cornelius1, Woodring E. Wright1, Michael A. White1, and Jerry W. Shay1. 1Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9039. 2Department of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77054. Supplementary Figure S1. K-rasV12 expressing cells are resistant to p53 induced apoptosis. Whole-cell extracts from immortalized K-rasV12 or p53 down regulated HCECs were immunoblotted with p53 and its down-stream effectors after 10 Gy gamma-radiation. ! Supplementary Figure S2. Quantitative validation of selected shRNAs for their ability to enhance soft-agar growth of immortalized shTP53 expressing HCECs. Each bar represents 8 data points (quadruplicates from two separate experiments). Arrows denote shRNAs that failed to enhance anchorage-independent growth in a statistically significant manner. Enhancement for all other shRNAs were significant (two tailed Studentʼs t-test, compared to none, mean ± s.e.m., P<0.05)." ! Supplementary Figure S3. Ability of shRNAs to knockdown expression was demonstrated by A, immunoblotting for K-ras or B-E, Quantitative RT-PCR for ERICH1, PTPRU, SLC22A15 and SLC44A4 48 hours after transfection into 293FT cells. Two out of 23 tested shRNAs did not provide any knockdown. " ! Supplementary Figure S4. shRNAs against A, PTEN and B, NF1 do not enhance soft agar growth in HCECs without oncogenic manipulations (Student!s t-test, compared to none, mean ± s.e.m., ns= non-significant).
    [Show full text]
  • CRNKL1 Is a Highly Selective Regulator of Intron-Retaining HIV-1 and Cellular Mrnas
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.04.934927; this version posted February 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 CRNKL1 is a highly selective regulator of intron-retaining HIV-1 and cellular mRNAs 2 3 4 Han Xiao1, Emanuel Wyler2#, Miha Milek2#, Bastian Grewe3, Philipp Kirchner4, Arif Ekici4, Ana Beatriz 5 Oliveira Villela Silva1, Doris Jungnickl1, Markus Landthaler2,5, Armin Ensser1, and Klaus Überla1* 6 7 1 Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander 8 Universität Erlangen-Nürnberg, Erlangen, Germany 9 2 Berlin Institute for Medical Systems Biology, Max-Delbrück-Center for Molecular Medicine in the 10 Helmholtz Association, Robert-Rössle-Strasse 10, 13125, Berlin, Germany 11 3 Department of Molecular and Medical Virology, Ruhr-University, Bochum, Germany 12 4 Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen- 13 Nürnberg, Erlangen, Germany 14 5 IRI Life Sciences, Institute für Biologie, Humboldt Universität zu Berlin, Philippstraße 13, 10115, Berlin, 15 Germany 16 # these two authors contributed equally 17 18 19 *Corresponding author: 20 Prof. Dr. Klaus Überla 21 Institute of Clinical and Molecular Virology, University Hospital Erlangen 22 Friedrich-Alexander Universität Erlangen-Nürnberg 23 Schlossgarten 4, 91054 Erlangen 24 Germany 25 Tel: (+49) 9131-8523563 26 e-mail: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.04.934927; this version posted February 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]